HOME >> BIOLOGY >> NEWS
Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting

Snowmass, Co. (September 9, 2004) Inflammatory Bowel Diseases, comprised of Crohn's Disease and ulcerative colitis, are for the most part incurable and their causes are still unknown. About 1 million Americans suffer from IBD and research around the world on new therapeutic strategies against IBD is being reported at a conference sponsored by the American Physiological Society.

Below are reports on three presentations.

  • Anti-adhesion therapy in the treatment of IBD Julian Panes and Josep M. Pique of the Gastroenterology Department of the Hospital Clinic Barcelona, Spain, note that the localization for leukocytes to inflammatory areas has key implications in the pathogenesis, diagnosis and treatment of IBD. A major effort has been directed toward identifying and characterizing the adhesion glycoproteins that enable leukocytes to bind to vascular endothelial cells. Drugs that specifically target adhesion molecules involved in leukocyte recruitment are effective in treating intestinal inflammation.

    They said that experimental models have shown that blockade of VLA-4, VCAM-1 and P-selectin afford significant amelioration of intestinal inflammation. In experimental models, response to adhesion molecule blockage varies according to the type of inflammatory intestinal condition. In humans VLA-4 immunoneutralization has been effective in inducing remission in Crohn's Disease, but no data is available for ulcerative colitis.

    The researchers call for experimental and clinical controlled trials comparing the effectiveness of different strategies of CAM blockade, and suggest that this therapeutic approach be compared with current therapies.

  • Platelet recruitment in intestinal inflammation modulated by ICAM-1, P-selectin, PSGL-1

    Researchers from LSU and the University of Muenster studied the mechanisms responsible for platelet-WBC and platelet-endothelial cell (EC) interactions that occur in exper
    '"/>



  • Contact: Mayer Resnick
    mresnick@the-aps.org
    301-634-7209
    American Physiological Society
    9-Sep-2004


    Page: 1 2 3

    Related biology news :

    1. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
    2. Novel approaches to current cellular therapies continue progress toward disease prevention
    3. Novel therapies show promise against myeloid leukemia
    4. Novel sensors help clear the air
    5. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
    6. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
    7. Novel therapeutic target identified in fight against Rheumatoid Arthritis
    8. Novel bacterium detoxifies chlorinated pollutants
    9. Novel flu vaccine shows promise in mice
    10. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician
    11. Novel method identifies hidden genes

    Post Your Comments:
    *Name:
    *Comment:
    *Email:


    (Date:4/16/2019)... ... 2019 , ... The Healthcare Technology Report is pleased to ... process was run to evaluate the hundreds of CEOs that lead exemplary organizations ... related areas. We gathered data on each nominee’s professional background and assessed them ...
    (Date:4/9/2019)... , ... April 09, 2019 , ... ... clinical outcomes, today announced a new partnership with Ambry Genetics, a leading clinical ... access to state-of-the-art clinical genetic testing and family history assessment, so they may ...
    (Date:4/4/2019)... ... , ... The live session taking place on ... between product risk management (ISO 14971) and the clinical risk management process (ISO ... increasing global regulation and reimbursement challenges faced by medical device companies, it is ...
    Breaking Biology News(10 mins):
    (Date:4/8/2019)... ... April 09, 2019 , ... To support the global fight ... Biohub (CZ Biohub) has chosen Geneious Biologics to help them analyze and compare ... efforts to establish new approaches to inform the discovery of antibody-based diagnostics, new ...
    (Date:3/29/2019)... VIEW, Calif. (PRWEB) , ... March 28, 2019 ... ... achievement of development and testing milestones, CARB-X has proceeded with a second stage ... receive up to $1.7 million, which is on top of the $1.7 million ...
    (Date:3/27/2019)... WESTBURY, N.Y. (PRWEB) , ... March 27, 2019 , ... ... booth #60 at the Clayton Hotel Burlington Road, Dublin, Ireland. The executive team on ... Future and Pharma 4.0, two key tracks on the agenda this year. , Executives ...
    (Date:3/19/2019)... ... 2019 , ... The AACR annual conference pulls together a diverse group of ... cancer research. The Visikol team will be at the show at booth #3252 and ... as their digital pathology services . “For AACR this year we are highlighting ...
    Breaking Biology Technology:
    Cached News: